Isomorphic Labs Scores $5B to Push AI Drug Candidates Toward Clinics

Isomorphic Labs, a biotech venture spun out of Google’s DeepMind in 2021, has raised a fresh $5 billion in a wildly oversubscribed Series C funding round. The injection of capital marks a major leap forward in the company’s goal of moving AI-designed drug candidates into early-stage clinical trials. Greenoaks and Sequoia Capital led the round, joined by a mix of new and existing backers including Andreessen Horowitz, GV, Thrive Capital, Temasek, MGX, and the UK’s Sovereign AI Fund. All previous investors also took part.

From Protein Folding to Drug Design

The company leverages AI to simulate various realms of chemistry, building on breakthroughs such as DeepMind’s AlphaFold model, which can predict 3D structures of proteins from genetic sequences. With this engine, Isomorphic Labs has already harvested positive preclinical results in oncology and immunology—two of the most complex and high-risk areas in drug development. It has also struck partnerships with large pharmaceutical firms like Eli Lilly, Novartis, and Johnson & Johnson to help bring its AI drug candidates closer to real-world impact.

New Funds, Bigger Ambition

This Series C follows a previous $2.1 billion raise in May, and the latest capital will be used to both enhance the core drug-design AI platform and expand into additional therapeutic areas beyond its current oncology and immunology focuses. It’s the first major funding round since CEO Demis Hassabis left his role at DeepMind to dedicate himself full-time to leading Isomorphic Labs, while also transitioning to chairman of DeepMind. Hassabis, along with former DeepMind director John Jumper, received the Nobel Prize in Chemistry for their collaborative work on AlphaFold.

The company did not publicize a valuation for this round, although reports suggest it was targeting about $50 billion. This comes amid growing investor enthusiasm for ventures that apply AI to shorten the journey from discovery to clinic, a notoriously long and expensive path.

Why this matters: Isomorphic Labs is pushing the envelope on what’s possible when advanced algorithms tackle the toughest challenges in drug discovery—from understanding protein structures to designing medicines that might one day treat cancer or immune disorders. If its AI models continue to validate in clinical trials, this could shift how the pharma industry identifies and develops new therapies, potentially speeding up approval timelines and reducing costs.